Get the Stockscreener App
3.34
1.76%
-0.06
After Hours:
3.34
Cytek Biosciences Inc stock is traded at $3.34, with a volume of 3.05M.
It is down -1.76% in the last 24 hours and down -12.11% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$3.40
Open:
$3.41
24h Volume:
3.05M
Relative Volume:
3.07
Market Cap:
$423.04M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-37.11
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
+28.96%
1M Performance:
-12.11%
6M Performance:
-48.93%
1Y Performance:
-41.71%
1-Day Range:
$3.26
$3.53
1-Week Range:
$2.54
$3.53
52-Week Range:
$2.37
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
3.34 | 328.05M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
133.94 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.83 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.10 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.00 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.77 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Bank of America Corp DE Boosts Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences Leads Our Top 3 Penny Stock Selections - Yahoo Finance
ProShare Advisors LLC Has $235,000 Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Jane Street Group LLC - Defense World
Ameriprise Financial Inc. Has $1.62 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System - MSN
Optimizing Lab Efficiency with Cytek's Aurora Evo Flow Cytometer - Lab Manager
The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31% - simplywall.st
Where are the Opportunities in (CTKB) - news.stocktradersdaily.com
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - SINA HONG KONG LIMITED
Cytek® Biosciences Is Setting the New Standard for Full - GlobeNewswire
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - GlobeNewswire Inc.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Millennium Management LLC - Defense World
Deutsche Bank AG Acquires 36,542 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Given New $7.00 Price Target at Morgan Stanley - Defense World
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cytek Management Sets Key Investor Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock - Benzinga
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 10% drop adds to a year losses - simplywall.st
Cytek Biosciences stock hits 52-week low at $2.5 amid market challenges - Investing.com Canada
BNP Paribas Financial Markets Takes Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
(CTKB) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stake Raised by Northern Trust Corp - Defense World
Cytek Biosciences (CTKB) Faces Price Target Cut Amid Weak Market Dynamics | CTKB Stock News - GuruFocus
Price T Rowe Associates Inc. MD Boosts Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Goldman Sachs Maintains 'Sell' Rating on Cytek Biosciences (CTKB - GuruFocus
Cytek Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Call Transcript - Insider Monkey
Dimensional Fund Advisors LP Grows Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (CTKB) Downgraded to Hold as Challenges Persis - GuruFocus
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cytek Biosciences: Earnings Call Reveals Mixed Fortunes - TipRanks
Cytek Biosciences stock rating cut, price target drops to $4 By Investing.com - Investing.com Nigeria
Cytek Biosciences stock rating cut, price target drops to $4 - Investing.com
TD Cowen Downgrades Cytek Biosciences to Hold From Buy, Adjusts Price Target to $4 From $7 - marketscreener.com
Cytek Biosciences (CTKB) Downgraded to Hold as Challenges Persist | CTKB Stock News - GuruFocus
Cytek Biosciences Faces Revenue Challenges and Market Uncertainty, Downgraded to Hold - TipRanks
Cytek Biosciences Inc (CTKB) Q1 2025 Earnings Call Highlights: Navigating Growth Amid Market ... By GuruFocus - Investing.com Canada
Cytek Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Cytek Biosciences Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Cytek Biosciences misses Q1 2025 earnings forecasts - Investing.com
Cytek Biosciences, Inc. SEC 10-Q Report - TradingView
Cytek Biosciences (CTKB) Reports Q1 Revenue Below Expectations | CTKB Stock News - GuruFocus
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):